Enliven Therapeutics, Inc.

ELVN Healthcare Biotechnology

In the quarter to June 2026, EPS was flat and free cash flow fell 8.34%, each against the same quarter a year earlier.

37.32 2.01 −5.11%
Market cap
$2.9B
P/E
0.0×
Fwd P/E
—
Dividend yield
—
F-score
n/a
Altman Z
n/a
Beneish M
n/a
Dividend safety
n/a
Jun '26 Mar '26 Dec '25 Sep '25 Older periods
Current Ratio
64.07 40.32 28.66 32.95

+8 more quarters

Net Debt/EBITDA
24.40 16.43 13.53 18.84
Debt/Equity
0.00 0.00 0.00 0.00
Free Cash Flow per Share
(0.28) (0.31) (0.28) (0.21)
Book value per Share
13.53 7.22 8.11 7.67
Free Cash Flow
(18.63) (19.29) (15.62) (13.28)
Other line items

Show all line items

Columns are period end dates